Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the <scp>LEADER</scp> randomized trial

Ofri Mosenzon(Hebrew University of Jerusalem), Hiddo J.L. Heerspink(University Medical Center Groningen), Bernt Johan von Scholten(Novo Nordisk (Denmark)), Johannes F.E. Mann(Katholische Stiftungshochschule München), Itamar Raz(Hebrew University of Jerusalem), Stephen C. Bain(Swansea University), Peter Rossing(Steno Diabetes Centers), Richard E. Pratley(Translational Research Institute for Metabolism and Diabetes), Søren Rasmussen(Novo Nordisk (Denmark)), Frederik Persson, Thomas Idorn(University of Copenhagen)
Diabetes Obesity and Metabolism
July 3, 2020
10.1111/dom.14126
Cited by 24

Related Papers

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2020|2.6k
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
|Diabetes Care|2022|1.9k